Trials / Completed
CompletedNCT00456716
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
A Phase II Trial of Sorafenib in BAC or Never-Smokers With Any Lung Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Swedish Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label study of sorafenib
Detailed description
Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers (less than \< 100 cigarettes lifetime).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sorafenib | 400mg po bid |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-04-05
- Last updated
- 2010-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00456716. Inclusion in this directory is not an endorsement.